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Abstract
Introduction Measles, mumps, rubella, and varicella
combination vaccines (MMRV) facilitate varicella vacci-
nation uptake compared with separate administration of
measles, mumps, and rubella vaccine (MMR) with vari-
cella vaccine (V). However, the risk of developing febrile
convulsions (FC) is higher in children vaccinated with
MMRV.
Objectives The aim was to demonstrate how to put the
increased FC risk associated with MMRV into perspective
by comparing it with the lower V-coverage risk associated
with MMR ? V.
Methods FC and varicella burdens were measured by
total numbers or duration of hospitalisations. A model,
based on several assumptions and integrating parameters
from heterogeneous data sources relevant to Germany, was
developed to evaluate hospitalisation ratios (HRs; ratios
between yearly numbers of varicella-related hospitalisation
days prevented by MMRV and yearly numbers of FC-re-
lated hospitalisation days attributed to MMRV, both
compared with MMR ? V). A sensitivity analysis esti-
mated HR under different scenarios beyond the German
experience.
Results For parameter values compatible with the Ger-
man experience, where MMRV (Priorix-TetraTM, GSK,
Belgium) was introduced in 2006, the model predicted that
transitioning from MMR ? V to MMRV would induce
225 vaccine-related FC hospitalisation days whilst
preventing 1976 varicella-related hospitalisation days per
year. The HR estimated by Monte Carlo simulations was
8.5 (95 % confidence interval: 1.99–25.22). A sensitivity
analysis on two key parameters suggested that transitioning
from MMR ? V to MMRV would be favourable in situa-
tions where MMRV use would significantly impact vari-
cella vaccination uptake.
Conclusions MMRV use instead of MMR ? V can sub-
stantially reduce the number of hospitalisation days,
despite increased FC risk when MMRV is used as a first
dose of measles-containing vaccine.
Key Points
Our modelling suggests that the use of measles,
mumps, rubella, and varicella combination vaccines
(MMRV) instead of measles, mumps, and rubella
vaccine with varicella vaccine (MMR ? V) can
substantially reduce the number of hospitalisation
days via higher vaccination coverage against
varicella, despite the observed increased risk of
febrile convulsions when MMRV is used as a first
dose of measles-containing vaccine.
The net result of these two opposing effects is one of
the trade-offs between the two vaccination schemes
that needs to be considered when making decisions
on their use in immunisation programmes.
This proof-of-concept analysis has demonstrated the
feasibility and usefulness of quantitative modelling
approaches, based on the combination of
heterogeneous data sources, to provide objective,
rational, and transparent information.
& Vincent Bauchau
vincent.g.bauchau@gsk.com
1 GSK Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium
Drug Saf (2015) 38:1095–1102
DOI 10.1007/s40264-015-0326-4
1 Introduction
Combination vaccines are used to simplify the recom-
mended immunisation schedules, decrease the number of
healthcare visits and injections in children, and improve
vaccination coverage and compliance [1, 2]. Therefore,
measles, mumps, rubella, and varicella combination vac-
cines (MMRV) have been developed to replace the sepa-
rate administration of the trivalent measles, mumps, and
rubella vaccine (MMR) with the monovalent varicella
vaccine (V). As seen with other combination vaccines,
MMRV has been a key driver in improving the vaccination
coverage against varicella in various countries, such as
Germany and the USA [3–8].
German data suggest that V uptake was suboptimal when
separate administration of MMR ? V was recommended.
Indeed, some parents are willing to vaccinate their child
against MMR, but do not accept separate V and MMR
vaccination. The main factors associated with the low
acceptance rate of V vaccination by parents are the recom-
mendations of paediatricians, who often have doubts about
the benefits of varicella vaccination as they rarely observe
severe complications in their practices; a negative attitude
towards vaccination in general; parents doubts about vac-
cine safety and effectiveness; and the perception that vari-
cella is a mild disease [5, 7, 8]. Data from Germany, where
MMRV was introduced in 2006, also showed that, even
when MMRV was widely used, varicella vaccination cov-
erage and timeliness of vaccination could still be improved
[9]. Data from a national sentinel network led by the Robert
Koch Institute suggested that varicella vaccination coverage
in Germany was 78 % in 2008 [10]; however, this could be
an overestimation of the real coverage since the network
may not be representative of the entire country [6].
In children, the risk of febrile convulsions (FC) is
increased during the first 2 weeks following MMR vacci-
nation [11, 12]. In addition, more recent studies have shown
that this risk was about two times higher in children vac-
cinated with the first MMRV vaccine licensed worldwide
(ProQuad, Merck & Co., Inc., Whitehouse Station, New
Jersey, USA) compared with the separate administration of
MMR ? V [13, 14]. Later, a study conducted by the Bre-
men Institute for Epidemiology and Prevention Research
showed that the risk of developing FC within 5–12 days
post-vaccination was also higher in children younger than 5
years who received the other licensed MMRV vaccine
(Priorix-TetraTM, GSK, Belgium) compared with separate
injections of MMR ? V or MMR alone [15]. A further
study provided similar risk estimates from Canada [16].
These observations suggest that both MMRV vaccines,
when used as a first dose of measles-containing vaccine, are
associated with an increased risk of FC [17].
While combined MMRV vaccines can potentially
increase the number of FC cases, they can decrease the
number of varicella cases through increased coverage for
the V component. Here, we present an attempt to assess the
net result of these two opposing effects (Fig. 1). This
comparison would ideally be made by counting the hos-
pitalisations for FC and varicella, and their duration, in a
number of large populations randomly allocated to MMRV
and MMR ? V schemes, over several years, and with
everything else being equal. As this is hardly feasible, we
selected a modelling approach and the recent experience in
Germany as a starting point. In Germany, a general vari-
cella immunisation for infants from the age of 11 months
was introduced in 2004, followed by the subsequent rec-
ommendation of a second vaccine dose at 15–23 months of
age in 2009. Priorix-TetraTM was licensed in July 2006,
and both vaccination schemes (MMR ? V and MMRV)
have been widely used; this has favoured comparison
between the two vaccination regimens in a previous study
conducted by the Bremen Institute for Epidemiology and
Prevention Research [15]. In our analysis, we first used
German data to put the increased risk of FC associated with
MMRV (Priorix-TetraTM) into perspective by comparing it
with the higher risk of varicella infection associated with
the MMR ? V regimen. Then, we expanded this analysis
to other scenarios beyond the German experience.
2 Methods
In this quantitative analysis, the increased risk of FC
associated with MMRV (Priorix-TetraTM) was contrasted
with the higher risk of varicella infections associated with
Fig. 1 Schematic representation of the two competing vaccination
schemes and their associated risks and benefits as selected for the
current analysis. *The (small) fraction of the total population who is
not properly vaccinated against MMR. FC febrile convulsions, MMR
measles, mumps, and rubella vaccine, MMRV measles, mumps,
rubella, and varicella vaccine, V varicella vaccine
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the separate MMR ? V vaccination approach (Fig. 1). We
used a model based on several assumptions to integrate
parameters from heterogeneous sources of data from Ger-
many (in the period 2006–2008). Statistical uncertainty
was evaluated through a probabilistic uncertainty analysis
by Monte Carlo simulations. In addition, to address the
potential variability between countries or over time,
structural uncertainty was assessed through a sensitivity
analysis.
The assumptions, as well as the point estimates for the
input parameters, are described in Table 1, and were
selected to mimic the situation in Germany in the period
2006–2008. The risk estimates were derived from the post-
marketing study conducted by the Bremen Institute for
Epidemiology and Prevention Research among children
who received a first vaccination with MMRV (Priorix-
TetraTM), MMR, or MMR ? V between January 2006 and
December 2008 [15]. Whereas the German vaccination
programme changed to a two-dose schedule for MMRV or
MMR ? V in 2009, only the first doses were taken into
account in this population-based analysis.
The primary health outcome in this analysis was the
duration of hospitalisation (median length of stay), which
was chosen as a measure of the burden of both FC and
varicella infection. Yearly attributable numbers of hospi-
talisation days were estimated for each vaccination regi-
men. The secondary health outcome in this analysis was
the number of hospitalisations.
2.1 Modelling Assumptions
The model was based on the following assumptions:
• Vaccination with V occurred only in co-administration
with MMR.
• MMR vaccination coverage and effectiveness were
considered as identical between the MMR ? V and the
MMRV regimens.
• Vaccination coverage of V varied between the two
vaccination regimens.
• Vaccine effectiveness of V was considered identical
under both vaccination regimens [18–20].
• One dose of V conferred identical and total protection
against varicella-related hospitalisation under both
vaccination regimens [21].
• The two vaccination regimens were compared as if they
had been implemented for a sufficient amount of time
as to reach a steady state in the dynamics of the disease,
and all effects were assumed to be linear [22].
• The incidence of adverse events leading to hospitali-
sation, other than FC in the period of 5–12 days after
the first dose, were considered identical under both
vaccination regimens [18, 23].
• There were no health consequences later in life from
hospitalisation for FC or varicella [24, 25].
• The number of hospitalisations for varicella after
introduction of routine varicella vaccination was
linearly proportional to the proportion of unvaccinated
children.
2.2 Calculation of the Hospitalisation Ratio
To quantify the benefit, we calculated the number of hos-
pitalisation days and the number of hospitalisations for
Table 1 Definitions and point estimates of the input parameters, and uncertainty of these parameters observed in the Monte Carlo simulations
Parameter Point estimate Sources Distribution Simulation,
median (95 % CI)
P1 Incidence of FC in days 5–12 after MMRV
(number of FC per child)
51/82,436 [15] Poisson 61.9 (46.1–78.9)a
P2 Incidence of FC in days 5–12 after MMR
(number of FC per child)
21/82,469 [15] Poisson 25.5 (15.8–36.4)a
P3 Relative probability of hospitalisation for FC
as compared with the German data from 2006–2008
1.0 [15] Constant 1 (–)
P4 Number of hospitalisations for varicella per year
(before the introduction of routine vaccination
against varicella, across all age groups)
1996 [24] Normal 1998 (1365–2633)
P5 Median LOS for FC (number of days) 1 [26] Constant 1 (–)
P6 Median LOS for varicella (number of days) 5 [24] Poisson 5 (1–10)
P7 MMR coverage for the first dose 0.9 [8] Constant 0.9 (–)
P8 Probability of V vaccination along with MMR vaccination 0.78 [10] Constant 0.78 (–)
P9 German birth cohort size (year 2005) 685,795 National statistics Constant 685,795 (–)
CI confidence interval, FC febrile convulsions, LOS length of stay in hospital, MMR measles, mumps, and rubella vaccine, MMRV measles,
mumps, rubella, and varicella vaccine, P parameter, V varicella vaccine
a Cumulative incidence per 100,000 children
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varicella that could be averted when using MMRV instead
of MMR ? V. The hospitalisation rate for varicella in
unvaccinated children was based on the yearly number of
varicella-related hospitalisations observed in Germany
before the introduction of routine varicella vaccination.
The yearly number of varicella-related hospitalisation days
and hospitalisations attributable to MMR ? V compared
with MMRV were estimated as follows (Table 1): (P6) 9
(P4) 9 (P7) 9 [1 - (P8)] and (P4) 9 (P7) 9 [1 - (P8)],
respectively.
To quantify the risk, we calculated the yearly number of
hospitalisation days and the number of hospitalisations for
FC that were attributable to MMRV compared with MMR
or MMR ? V. The yearly population at risk was the
fraction of the birth cohort vaccinated with MMRV. The
yearly number of hospitalisation days and hospitalisations
for FC attributable to MMRV compared with MMR ? V
were estimated from the differences between the incidence
of FC under both vaccination regimens as follows
(Table 1): (P5) 9 (P9) 9 (P7) 9 [(P1) - (P2)] 9 (P3)
and (P9) 9 (P7) 9 [(P1) - (P2)] 9 (P3), respectively.
The hospitalisation ratio (HR) was the ratio between the
excess number of hospitalisation days (primary outcome)
or hospitalisations (secondary outcome) attributable to
varicella when vaccinating with MMR ? V compared with
MMRV, and the excess number of hospitalisation days
(primary outcome) or hospitalisations (secondary outcome)
attributable to vaccine-related FC when vaccinating with
MMRV compared with MMR ? V.
2.3 Probabilistic Uncertainty Analysis
The statistical variability of each non-constant input
parameter of the model was used to evaluate the statistical
uncertainty of the HR through a probabilistic analysis
based on Monte Carlo simulations. The most relevant
statistical distribution was selected for each input param-
eter, and 100,000 sets with randomly generated values for
all input parameters were produced. The point estimate
from the Monte Carlo simulation was defined as the
median of the 100,000 values, and the 95 % confidence
interval (CI) was derived from the observed percentiles.
Rather surprisingly, data from the Bremen Institute for
Epidemiology and Prevention Research indicated a med-
ian duration of hospitalisation for FC of 2–3 days during
the first month following MMR or MMRV vaccination in
2006–2008, with several cases having a relatively long
duration of up to 17 days. However, since the most recent
German guidelines include no indication on whether
children with FC should be hospitalised or not, the
duration of hospitalisation for FC was based on the most
recent international recommendations [26] and set to a
value of 1 day in this analysis (Table 1). A study
conducted in 1985 in the UK already suggested that
children who had been observed for 24 h after FC could
be discharged from hospital if the diagnosis of the cause
of fever had been established and the children were
medically fit, even if they were still febrile [27]. With
current vaccination schedules, the risk of meningitis has
become extremely low, and it is not recommended any-
more to carry out unnecessary investigations in most
children presenting with FC [26].
Current international recommendations for the man-
agement of FC advocate minimal intervention [26–29]. In
Germany, the Bremen Institute for Epidemiology and
Prevention Research reported that hospitalisation rates for
FC in 2006–2008 were around 60 % in 9- to 17-month-old
children; this estimation was based on different case defi-
nitions for hospitalised and non-hospitalised children, and
did not take into account the timing of MMR or MMRV
vaccination. In a study conducted in the USA, hospitali-
sation rates for FC were 6 and 17 % during 7–10 days
following MMRV and MMR ? V vaccination, respec-
tively [14]. In another study, hospitalisation rates dropped
significantly after implementation of updated guidelines for
the management of children with FC (from 57.3 to 20.5 %
and from 16.9 to 3.2 % in two large hospitals in France and
Italy, respectively) [28].
2.4 Sensitivity Analysis
We identified the two parameters that are most likely to
vary largely between countries or over time and have a
large effect on the HR: rates of hospitalisation for FC and
vaccination coverage for V under MMR ? V. A sensitivity
analysis was conducted to explore the structural uncer-
tainty of HR in situations where the values of these two
parameters were changed over their potential range. Monte
Carlo simulations were used to derive the different values
of both the relative probability of hospitalisation for FC as
compared with the German data from 2006–2008 (param-
eter P3) and the vaccination coverage for V under
MMR ? V (parameter P8), for which the point estimates
for the HR were 1. Statistical uncertainty was estimated as
explained above.
In the study of the Bremen Institute for Epidemiology
and Prevention Research, the probability of hospitalisation
for FC was 100 % by definition since only hospitalised
cases were included in the analysis [15]. However, in the
German national context, the probability of hospitalisation
for FC is not 100 % and is considered to be close to 80 %.
To allow for generalisation, the model was slightly modi-
fied in order to use the national probability of hospitalisa-
tion for FC instead of the one related to the specific study
of the Bremen Institute for Epidemiology and Prevention
Research.
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In order to differentiate the parameter space where the
HR could be considered to be significantly higher than 1,
we also derived the parameter values for which the lower
limit of the 95 % CI around the HR was 1.
3 Results
3.1 Modelling Based on the German Experience
The estimates for the different input parameters used in the
model were selected from heterogeneous sources of data as
described in Table 1 [8, 10, 15, 24]. When using these
point estimates for all parameters, the model predicted
1976 days of hospitalisation (395.4 hospitalisations) for
varicella averted when the MMRV vaccination regimen
was used, compared with 225 days of hospitalisation
(225.0 hospitalisations) for FC attributable to MMRV. The
point estimate of the HR was close to 11 in the primary
analysis, which was based on the number of hospitalisation
days.
When the random variability of each non-constant
input parameter of the model was estimated by a Monte
Carlo probabilistic uncertainty analysis, the median HR
was 8.48 (95 % CI: 1.99–25.22) in terms of hospitalisa-
tion days and 1.76 (0.98–4.02) in terms of number of
hospitalisations (Table 2). The difference with the point
estimate presented above may be explained by the non-
symmetrical distribution of the HR. In the primary anal-
ysis, the lower limit of the 95 % CI around the HR was
above 1, indicating that the number of hospitalisation days
attributable to non-prevented varicella when using
MMR ? V as compared with MMRV was significantly
higher than the number of hospitalisation days attributable
to FC after MMRV as compared with MMR ? V at a
95 % CI (Table 2).
3.2 Sensitivity Analysis
Expected outcomes in other countries or under different
scenarios were derived from a sensitivity analysis, which
was based on two key parameters: the vaccination coverage
of V when co-administered with MMR and the probability
of being hospitalised for FC. The point estimate of the HR
in terms of hospitalisation days was higher than 1 for
scenarios where the probability of being hospitalised for
FC was less than 40 times the probability of not receiving
V along with MMR (Fig. 2).
In countries where the mean duration of hospitalisation
for varicella was different than in Germany (e.g. 3 days
instead of 5 days), the slope of the discriminating line,
which is shown in Fig. 2, would be corrected by the same
ratio (e.g. 40 9 3/5 = 24). When considering the line for
the 95 % CI limit in Fig. 2, the main driver was the
probability of not receiving V along with MMR.
4 Discussion
The results of our analysis using German data suggested
that the predicted number of hospitalisation days induced
by the increase risk of FC associated with MMRV is lower
than that induced by higher risk of varicella infection
associated with the MMR ? V regimen. The expansion of
this analysis to other scenarios beyond the German expe-
rience suggested that transitioning from MMR ? V to
MMRV would be favourable in situations where MMRV
use would significantly impact varicella vaccination
uptake.
For parameter values compatible with the recent expe-
rience in Germany, the model suggested that transitioning
from MMR ? V to MMRV would reduce the yearly
number of hospitalisation days; although there may be 225
hospitalisation days attributable to vaccine-related FC, at
the same time, 1976 hospitalisation days due to severe
varicella could be averted by using MMRV instead of
MMR ? V. When Monte Carlo simulations were used to
evaluate the statistical uncertainty, the median HR was
estimated to be 8.5 (95 % CI 1.99–25.22). Since these
estimations were derived from a model based on several
assumptions and using heterogeneous sources of data, this
quantitative analysis should be used along with other rel-
evant considerations for any overall benefit/risk assessment
of MMRV compared with MMR ? V.
A sensitivity analysis was performed to estimate HR
under different scenarios, which were based on existing or
Table 2 Benefit and risk
estimates in terms of number of
hospitalisation days in Germany
Name Mean Median 95 % CI
Yearly number of hospitalisation days for FC
attributable to MMRV (risk)
225.0 224.7 104.9–351.9
Yearly number of hospitalisation days for
varicella prevented under MMRV (benefit)
1989 1879 433.4–4125
Hospitalisation ratio 8.5 1.995–25.22
CI confidence interval, FC febrile convulsions, MMRV measles, mumps, rubella, and varicella vaccine
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hypothetical situations, and could represent other countries
or other times when vaccine recommendations or use were
different. This modelling approach, with all its limitations,
suggested that, in situations where MMRV use would
significantly impact varicella vaccination uptake, the use of
MMRV instead of MMR ? V would be favourable. For
any further use of these results, it is critical to consider the
model assumptions and assess their relevance before
making any decision on the use of MMRV in immunisation
programmes.
The results are based on a modelling approach with
several limitations, including:
• The model did not consider situations where V was co-
administered with the second MMR dose (either as
MMR ? V or MMRV) if it was not co-administered
with the first MMR dose.
• The assumption of total protection against hospitalisa-
tion could have overestimated the benefit measure of
the MMRV compared with the MMR ? V vaccination
regimen.
• The measures of the burden of both FC and varicella
infection that were selected in this analysis (days of
hospitalisation and number of hospitalisations) may not
have completely captured the severity of the two
medical conditions; hospitalisation for FC is generally
more a measure of precaution, while hospitalisation
related to varicella infection generally indicates a
serious medical concern.
• The model did not take into account the potential
impact of the recommendation to administer the first
doses of MMR and V separately in Germany since
2011 [3].
• The model did not take into account the effect of herd
immunity, which is relevant in the context of protection
against varicella. This is a conservative approach since
such an effect would increase the benefit of MMRV
compared with MMR ? V.
5 Conclusion
A modelling approach can be used to estimate the overall
impact of different vaccine regimens on some specific
outcomes. The model used in this analysis suggested that
transitioning from MMR ? V to MMRV may substantially
reduce the number of hospitalisation days, despite the
observed increased risk of FC when MMRV was used as a
first dose of measles-containing vaccine. This proof-of-
concept analysis has demonstrated the feasibility and use-
fulness of quantitative modelling approaches, based on the
combination of heterogeneous data sources, to provide
objective, rational, and transparent information. However,
all assumptions and limitations should be kept in mind. In
addition, our model only assessed one of the multiple
trade-offs between the two vaccination regimens that need
to be considered when making decisions on their use in
immunisation programmes. In the future, more extensive
research could be performed to address unanswered ques-
tions, such as analyses using quality-adjusted life-years as
an outcome instead of the length and number of hospital-
isations, and analyses taking into account indirect effects,
such as herd immunity or increased hesitancy to accept
MMRV due to knowledge of the increased risk of FC.
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